Program
balcinrenone
Also written as “AZD9977”, “Balcinrenone/dapagliflozin” and “balcinrenone/ dapagliflozin”.
Its studies are mostly in Heart Failure · Renal Insufficiency · Renal Insufficiency, Chronic · Fasting · Cardiovascular Diseases, led by AstraZeneca.
Drug pageAZD9977: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 151 open or running | phase 3since May 29, 2026 | Jun 18, 2015 | Jul 1, 2030phase 3 · NCT07624305 |
- Named in AstraZeneca’s own pipeline as
balcinrenone/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea, Parexel and Quotient Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jun 18, 2015.
- Aug 24, 2015Phase 1 study in PharmacodynamicsNCT02532998 · 40 enrolled · United Kingdom
- Sep 24, 2015Phase 1 study in PharmacokineticsNCT02560363 · United Kingdom
- Jan 25, 2018Phase 1 study in Heart FailureNCT03435276 · 27 enrolled · United Kingdom
- Feb 15, 2018Phase 1 study in Heart FailureNCT03450759 · 13 enrolled · United Kingdom
- Sep 21, 2018Phase 1 study in Heart FailureNCT03682497 · 68 enrolled · Bulgaria, Czechia, Poland and more
- Dec 12, 2018Phase 1 study in Heart FailureNCT03801967 · 28 enrolled · United Kingdom
- Feb 14, 2019Phase 1 study in Heart FailureNCT03843060 · 14 enrolled · United States
- Jun 19, 2020Phase 1 study in Renal InsufficiencyNCT04469907 · 18 enrolled · United States
- Dec 17, 2020Phase 1 study in Cardiovascular DiseasesNCT04686591 · 8 enrolled · United Kingdom
- Jan 25, 2022Named balcinrenoneINNProposed as its International Nonproprietary Name in WHO's List 126 · before, AZD9977
- Apr 16, 2024Phase 1 study in Hepatic ImpairmentNCT06388616 · 30 enrolled · United States
- Sep 25, 2024Phase 1 study in Healthy VolunteerNCT06651021 · 10 enrolled · China
- May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT06979388 · 14 enrolled · United Kingdom
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicPhase 3 reachedNCT07624305 · 2,800 planned · United States, Argentina, Austria and more
- Jul 13, 2026Phase 1 study in Renal InsufficiencyNCT07754331 · 10 enrolled · United States
Ahead
- Jul 1, 2030Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07624305
TargetBeta
“Mineralocorticoid receptor modulator”ChEMBL 37, by rule
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 25 |
| drospirenonerule | estetra | phase 4 | 20 |
| Spironolactonerule | cmp-development-llc | phase 4 | 8 |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 7 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07754331Renal Insufficiency · United States | 1 | Completed | Oct 6, 2026 | 10 |
| NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more | 3 | Recruiting | Jul 1, 2030 | 2,800 |
| NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom | 1 | Completed | Jul 12, 2025 | 14 |
| NCT06651021Healthy Volunteer · China | 1 | Completed | Oct 28, 2024 | 10 |
| NCT06388616Hepatic Impairment · United States | 1 | Completed | Sep 5, 2024 | 30 |
| NCT04686591Cardiovascular Diseases · United Kingdom | 1 | Completed | Feb 4, 2021 | 8 |
| NCT04469907Renal Insufficiency · United States | 1 | Completed | Oct 28, 2021 | 18 |
| NCT03843060Heart Failure · United States | 1 | Completed | Apr 1, 2019 | 14 |
| NCT03801967Heart Failure · United Kingdom | 1 | Completed | May 2, 2019 | 28 |
| NCT03682497Heart Failure · Bulgaria, Czechia, Poland and more | 1 | Terminated | Mar 31, 2020 | 68 |
| NCT03450759Heart Failure · United Kingdom | 1 | Completed | Jun 6, 2018 | 13 |
| NCT03435276Heart Failure · United Kingdom | 1 | Completed | Jun 13, 2018 | 27 |
| NCT02560363Pharmacokinetics · United Kingdom | 1 | Withdrawn | Jan 2016 | 0 |
| NCT02532998Pharmacodynamics · United Kingdom | 1 | Completed | Dec 2015 | 40 |
| NCT02484729Safety · United Kingdom | 1 | Completed | Nov 2015 | 196 |
How it is read
Names in the registry
- “AZD9977”, 5 entries
- “Balcinrenone/dapagliflozin”, 2 entries
- “balcinrenone/ dapagliflozin”, 1 entry
- “balcinrenone/dapagliflozin”, 1 entry
- “Balcinrenone”, 1 entry
Codes read as this program: AZD9977.
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Renal Insufficiency, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Fasting, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.